JP6946575B2 - 眼の状態の治療のためのピロカルピン塩酸塩の使用 - Google Patents

眼の状態の治療のためのピロカルピン塩酸塩の使用 Download PDF

Info

Publication number
JP6946575B2
JP6946575B2 JP2020559558A JP2020559558A JP6946575B2 JP 6946575 B2 JP6946575 B2 JP 6946575B2 JP 2020559558 A JP2020559558 A JP 2020559558A JP 2020559558 A JP2020559558 A JP 2020559558A JP 6946575 B2 JP6946575 B2 JP 6946575B2
Authority
JP
Japan
Prior art keywords
volume
weight
pharmaceutical composition
eye
pilocarpine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020559558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021522256A (ja
Inventor
マイケル アール ロビンソン
マイケル アール ロビンソン
モハメド ディバス
モハメド ディバス
ジャヤ ギヤナニ
ジャヤ ギヤナニ
アヌラーダー ゴア
アヌラーダー ゴア
ソンウク リー
ソンウク リー
ハイシア リウ
ハイシア リウ
アイリーン モーガン
アイリーン モーガン
ジハオ チョウ
ジハオ チョウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66821312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6946575(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2021522256A publication Critical patent/JP2021522256A/ja
Priority to JP2021150116A priority Critical patent/JP7470667B2/ja
Application granted granted Critical
Publication of JP6946575B2 publication Critical patent/JP6946575B2/ja
Priority to JP2024062082A priority patent/JP2024096131A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2020559558A 2018-04-24 2019-04-24 眼の状態の治療のためのピロカルピン塩酸塩の使用 Active JP6946575B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021150116A JP7470667B2 (ja) 2018-04-24 2021-09-15 眼の状態の治療のためのピロカルピン塩酸塩の使用
JP2024062082A JP2024096131A (ja) 2018-04-24 2024-04-08 眼の状態の治療のためのピロカルピン塩酸塩の使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862662144P 2018-04-24 2018-04-24
US62/662,144 2018-04-24
US201862780117P 2018-12-14 2018-12-14
US62/780,117 2018-12-14
US201962790957P 2019-01-10 2019-01-10
US62/790,957 2019-01-10
PCT/US2019/028917 WO2019209955A2 (en) 2018-04-24 2019-04-24 Presbyopia treatments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021150116A Division JP7470667B2 (ja) 2018-04-24 2021-09-15 眼の状態の治療のためのピロカルピン塩酸塩の使用

Publications (2)

Publication Number Publication Date
JP2021522256A JP2021522256A (ja) 2021-08-30
JP6946575B2 true JP6946575B2 (ja) 2021-10-06

Family

ID=66821312

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020559558A Active JP6946575B2 (ja) 2018-04-24 2019-04-24 眼の状態の治療のためのピロカルピン塩酸塩の使用
JP2021150116A Active JP7470667B2 (ja) 2018-04-24 2021-09-15 眼の状態の治療のためのピロカルピン塩酸塩の使用
JP2024062082A Pending JP2024096131A (ja) 2018-04-24 2024-04-08 眼の状態の治療のためのピロカルピン塩酸塩の使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021150116A Active JP7470667B2 (ja) 2018-04-24 2021-09-15 眼の状態の治療のためのピロカルピン塩酸塩の使用
JP2024062082A Pending JP2024096131A (ja) 2018-04-24 2024-04-08 眼の状態の治療のためのピロカルピン塩酸塩の使用

Country Status (25)

Country Link
US (4) US10610518B2 (https=)
EP (2) EP3681500B2 (https=)
JP (3) JP6946575B2 (https=)
KR (2) KR20230079489A (https=)
CN (1) CN112272558A (https=)
AU (3) AU2019261598B9 (https=)
BR (1) BR112020021845A2 (https=)
CA (2) CA3162141A1 (https=)
CL (1) CL2020002734A1 (https=)
CO (1) CO2020014563A2 (https=)
CY (1) CY1125325T1 (https=)
DK (1) DK3681500T3 (https=)
ES (1) ES2920803T5 (https=)
HR (1) HRP20220762T1 (https=)
HU (1) HUE058931T2 (https=)
IL (1) IL278178A (https=)
LT (1) LT3681500T (https=)
MX (1) MX2020011301A (https=)
PH (1) PH12020551766A1 (https=)
PL (1) PL3681500T3 (https=)
PT (1) PT3681500T (https=)
RS (1) RS63360B1 (https=)
SG (1) SG11202010472XA (https=)
SI (1) SI3681500T1 (https=)
WO (1) WO2019209955A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3070556A1 (en) 2017-07-20 2019-01-24 Alan Laboratories, Inc. Compositions and methods for treatment of myopia
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
EP3866790A4 (en) 2018-10-15 2022-08-03 Ocuphire Pharma, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES
JP7670945B2 (ja) 2018-10-26 2025-05-01 オーパス・ジェネティクス・インコーポレイテッド 老眼、散瞳、および他の眼障害の治療のための方法および組成物
MX2023002946A (es) * 2020-09-11 2023-04-11 Intratus Nevada Inc Composiciones y metodos para tratar presbicia, hipermetropia, astigmatismo, estereopsis disminuida, y sensibilidad al contraste disminuida.
US11872213B2 (en) * 2021-01-28 2024-01-16 Glaukos Corporation Formulations
WO2022232205A1 (en) * 2021-04-28 2022-11-03 Lenz Therapeutics, Inc. A method of reducing brow ache
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
WO2023091439A1 (en) 2021-11-17 2023-05-25 Lenz Therapeutics, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
WO2023125544A1 (zh) 2021-12-28 2023-07-06 沈阳兴齐眼药股份有限公司 组合物及其在制备用于治疗老花眼的药物中的用途
US11857538B2 (en) 2022-01-14 2024-01-02 Somerset Therapeutics, Llc Stable pilocarpine formulations with modified buffer characteristics and related methods
US12156868B2 (en) 2022-02-09 2024-12-03 Somerset Therapeutics, Llc Formulations of pilocarpine and brimonidine compounds and related methods
CN119584954A (zh) 2022-04-21 2025-03-07 格劳科斯公司 眼用局部乳膏组合物
AU2023273823A1 (en) 2022-05-18 2024-12-05 Glaukos Corporation Novel applications of zwitterions in ophthalmic topical cream compositions and preparations
CN117243888A (zh) * 2023-09-22 2023-12-19 南京海纳制药有限公司 一种含有盐酸毛果芸香碱滴眼水性药物组合物及其制备方法
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474751A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Ophthalmic drug delivery system utilizing thermosetting gels
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
IL92351A (en) 1988-11-29 1994-02-27 Allergan Inc Irvine Aqueous opthalmic solutions containing stabilized chlorine dioxide and an inorganic salt
US5122522A (en) 1989-06-21 1992-06-16 The Trustees Of The University Of Pennsylvania Treatment and control of ocular development
US5055467A (en) 1989-11-13 1991-10-08 Allergan, Inc. Pharmaceutical epinephrine-pilocarpine compounds
US5496471A (en) 1990-01-08 1996-03-05 Ciba-Geigy Corporation Apparatus for removing components from solutions
US5776916A (en) 1990-07-10 1998-07-07 Gramer; Eugen Medicament for reducing the intraocular pressure
CA2064160C (en) 1991-03-27 1998-08-11 Paul J. T. Missel Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
JPH07508751A (ja) 1992-07-02 1995-09-28 テラー・オフサルミック・ファーマシューティカルズ・インコーポレーテッド 老視治療のための方法および生産品
SE512871C2 (sv) 1992-08-20 2000-05-29 Santen Oy Oftalmologisk beredning innehållande pilokarpin och ytterligare medel för behandling av okular hypertension
AU5599594A (en) * 1992-11-16 1994-06-08 Ciba-Geigy Ag Polyvinyl alcohol/borate ophthalmic drug delivery system
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
SE9401109D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Opthalmic composition II
US5574518A (en) 1995-01-10 1996-11-12 Les Laboratoires Opti-Centre Inc. System incorporation two different sphero-non-spherical contact lenses for correcting presbytia
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US6291466B1 (en) * 1998-07-30 2001-09-18 Allergan Sales, Inc. Cholinergic agents in the treatment of presbyopia
US6164282A (en) 1999-01-27 2000-12-26 Allergan Sales, Inc. Methods for restoring and/or enhancing accommodation in pseudo phakia
CH693625A5 (it) 1999-02-18 2003-11-28 Inpharma Sa Composizioni farmaceutiche contenenti composti ad attività promotrice di assorbimento di principi attivi.
IT1306135B1 (it) 1999-04-26 2001-05-30 Farmigea Spa Composizioni oftalmiche per il trattamento delle turbe visivecaratterizzate da ridotta sensibilita' al contrasto.
US6420407B1 (en) 1999-09-16 2002-07-16 Gerald Horn Ophthalmic formulation which modulates dilation
AU7581000A (en) 1999-09-16 2001-04-17 Gerald D. Horn A method for optimizing pupil size using alpha antagonist
TWI227143B (en) 1999-12-15 2005-02-01 Guo-Jiun Sung In situ gel formation for ophthalmic delivery by combining Pluronic/Carbopol medic composition and its preparing method
US6218428B1 (en) 2000-04-28 2001-04-17 Emil Chynn Ophthalmic composition
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
EP1328214A4 (en) 2000-09-20 2009-07-29 Shahinian Lee Jr NASAL, INHALABLE AND LOCAL OPHTHALMIC PREPARATIONS AND MEDICATIONS WITH SPONTANEOUS CONSERVATION
US6273092B1 (en) 2000-09-22 2001-08-14 Gerard M. Nolan Methods for treating various eye disorders
ITMI20010708A1 (it) 2001-04-03 2002-10-03 Alessandro Randazzo Trattamento farmacologico degli aloni notturni e delle immagini fantasma con parasimpaticomimetici diluiti aceclidina/pilocarpina dopo inter
US20030139737A1 (en) 2002-01-24 2003-07-24 J.T. Lin Method and apparatus for treatment of presbyopia by lens relaxation and anterior shift
CN101327325A (zh) 2002-07-30 2008-12-24 奥默罗斯公司 眼科冲洗液及方法
US20070211212A1 (en) 2002-09-26 2007-09-13 Percy Bennwik Eye state sensor
US20050261641A1 (en) 2002-09-26 2005-11-24 Warchol Mark P Method for ophthalmic administration of medicament
US20050205101A1 (en) * 2002-10-17 2005-09-22 Lin J T Combined pharmocological and surgical method and system for the treatment of eye disorders
US20040078009A1 (en) 2002-10-17 2004-04-22 Lin J. T. Method and apparatus for the treatment of presbyopia and other eye disorders combining pharmocological and surgical means
US20060177430A1 (en) 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
NZ540885A (en) 2002-12-20 2009-02-28 Chakshu Res Inc Ophthalmic formulation for the prevention and treatment of ocular conditions
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US20050119262A1 (en) 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
DE602005019724D1 (de) 2004-05-21 2010-04-15 Senju Pharma Co Ophthalmologische perkutan absorbierbare zubereitung enthaltend einen muscarin-rezeptor-agonist
US20050279369A1 (en) 2004-06-21 2005-12-22 Lin J T Method and apparatus for the treatment of presbyopia and glaucoma by ciliary body ablation
WO2006047534A1 (en) 2004-10-22 2006-05-04 Acufocus System and method for aligning an optic with an axis of an eye
EP1933833B8 (en) 2005-09-02 2011-09-14 Theravida, Inc. Therapy for the treatment of overactive bladder
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
MX2009000385A (es) 2006-07-12 2009-04-06 Univ Tennessee Res Foundation Acil-anilidas sustituidas y metodos de uso de las mismas.
ES2329161T3 (es) * 2006-12-18 2009-11-23 Jorge Luis Benozzi Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para su uso en el tratamiento de la presbicia.
CN101820917B (zh) 2007-10-08 2013-01-02 佛维雅制药股份有限公司 水性眼科配制剂
AU2015202175A1 (en) 2007-12-15 2015-05-14 Anant Sharma Optical correction
GB0724558D0 (en) 2007-12-15 2008-01-30 Sharma Anant Optical correction
WO2010125416A1 (en) 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2010135731A1 (en) 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
TW201109325A (en) 2009-07-30 2011-03-16 Wakamoto Pharma Co Ltd Aqueous composition for eye drops
AR081049A1 (es) 2010-08-17 2012-06-06 Gonzalez Santos Alejandro Raul Medicamento oftalmico para el tratamiento de la hipermetropia
KR101914940B1 (ko) * 2011-01-26 2018-11-06 알러간, 인코포레이티드 안과 질환을 치료하기 위한 안드로겐 조성물
UA113525C2 (xx) 2011-09-20 2017-02-10 Спосіб лікування пресбіопії
CA2849192C (en) 2011-10-12 2019-09-24 Ascendis Pharma Ophthalmology Division A/S Prevention and treatment of ocular conditions
AU2012351948A1 (en) 2011-12-16 2014-07-10 Allergan, Inc. Ophthalmic compositions comprising polyvinyl capralactam - polyvinyl acetate - polyethylene glycol graft copolymer
EP2630952A1 (en) 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
US10507245B2 (en) 2012-07-19 2019-12-17 Luis Felipe Vejarano Restrepo Ophthalmic formulation and method for ameliorating presbyopia
WO2014121027A1 (en) 2013-02-01 2014-08-07 Oculars Pharma, Llc Aqueous ophthalmic solutions of phentolamine and medical uses thereof
EP2950800B1 (en) 2013-02-01 2020-09-09 Ocuphire Pharma, Inc. Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
US9968594B2 (en) 2013-08-28 2018-05-15 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9089562B2 (en) 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia
US9314427B2 (en) 2013-08-28 2016-04-19 Presbyopia Therapies Llc Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
US8859623B1 (en) 2013-11-14 2014-10-14 Paragon BioTeck, Inc. Methods and compositions of stable phenylephrine formulations
ES2538551B1 (es) 2013-12-20 2016-01-13 Eurocanarias Oftalmológica, Sl Composición Oftálmica para la corrección de la presbicia
EP3093018B1 (en) 2014-01-10 2018-11-28 Santen Pharmaceutical Co., Ltd Pharmaceutical preparation including pyridylamino acetic acid compound
CN106456584A (zh) 2014-02-11 2017-02-22 阿拉西斯医药公司 用于矫正老视的药理学眼科用组合物和其施用
EP3302426A4 (en) * 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
US20190000808A1 (en) 2015-07-13 2019-01-03 Allergan, Inc. Composition and methods for the treatment of blephopharoptosis
CH711969A2 (it) 2015-12-29 2017-06-30 Pinelli Roberto Composizione per il trattamento della presbiopia.
US10231968B2 (en) 2016-08-01 2019-03-19 David R. Hardten Medicinal solution to be continuously or pulse-delivered to the eye for treating ophthalmological conditions/maladies
PT3500255T (pt) 2016-08-19 2023-01-10 Orasis Pharmaceuticals Ltd Composições farmacêuticas oftálmicas e utilizações relacionadas com estas
WO2018071619A1 (en) 2016-10-12 2018-04-19 Ps Therapies Ltd Artificial tear, contact lens and drug vehicle compositions and methods of use thereof

Also Published As

Publication number Publication date
US20240382462A1 (en) 2024-11-21
CA3162141A1 (en) 2019-10-31
US10610518B2 (en) 2020-04-07
CY1125325T1 (el) 2025-03-28
AU2019261598B9 (en) 2020-05-28
KR20230079489A (ko) 2023-06-07
HRP20220762T1 (hr) 2022-09-16
PT3681500T (pt) 2022-06-27
JP2021522256A (ja) 2021-08-30
SI3681500T1 (sl) 2022-09-30
MX2020011301A (es) 2021-01-29
AU2019261598B2 (en) 2020-05-14
CA3074618C (en) 2022-08-02
EP3681500A2 (en) 2020-07-22
HUE058931T2 (hu) 2022-09-28
PL3681500T3 (pl) 2022-08-01
SG11202010472XA (en) 2020-11-27
PH12020551766A1 (en) 2021-07-12
KR20210005134A (ko) 2021-01-13
CA3074618A1 (en) 2019-10-31
CO2020014563A2 (es) 2021-02-26
US20220241245A1 (en) 2022-08-04
EP3681500B2 (en) 2025-07-30
CN112272558A (zh) 2021-01-26
DK3681500T3 (da) 2022-06-27
AU2020203311A1 (en) 2020-06-11
AU2022201106A1 (en) 2022-03-10
EP3681500B1 (en) 2022-03-23
ES2920803T3 (es) 2022-08-09
US20210008034A1 (en) 2021-01-14
JP7470667B2 (ja) 2024-04-18
EP4066830A1 (en) 2022-10-05
JP2022008403A (ja) 2022-01-13
CL2020002734A1 (es) 2021-03-12
IL278178A (en) 2020-11-30
WO2019209955A3 (en) 2020-01-23
ES2920803T5 (en) 2025-11-11
BR112020021845A2 (pt) 2021-02-23
LT3681500T (lt) 2022-06-27
US20190321337A1 (en) 2019-10-24
US11285134B2 (en) 2022-03-29
AU2019261598A1 (en) 2020-03-19
JP2024096131A (ja) 2024-07-12
WO2019209955A2 (en) 2019-10-31
RS63360B1 (sr) 2022-07-29

Similar Documents

Publication Publication Date Title
JP6946575B2 (ja) 眼の状態の治療のためのピロカルピン塩酸塩の使用
JP7297308B2 (ja) 眼科用医薬組成物及びそれに関する使用
JP2022505950A (ja) 老眼、散瞳、および他の眼障害の治療のための方法および組成物
US20220175734A1 (en) Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
JP2022508715A (ja) 緑内障および関連状態の処置のための方法および組成物
Diestelhorst et al. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% tid in patients with open-angle glaucoma or ocular hypertension: a 6-month, randomized, multicenter study
Pepose et al. Reversal of pharmacologically induced mydriasis with phentolamine ophthalmic solution
US20230210821A1 (en) Using parasympathomimetic drugs alone or, in combination with one or more alpha agonists in pseudophakic patients, to create multi-focality
Sowka Phacomorphic glaucoma: case and review
US20260124178A1 (en) Presbyopia treatments
HK40081663A (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
Kim et al. Effects of brimonidine timolol fixed combination therapy on anterior ocular segment configuration
HK40034331A (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
HK40034331B (en) Use of pilocarpine hydrochloride for the treatment of presbyopia
RU2824137C2 (ru) Способы и композиции для лечения пресбиопии, мидриаза и других глазных расстройств
Wong What's new in contemporary ophthalmic drug delivery systems: Understanding the latest innovative technologies.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210514

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210514

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210804

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210816

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210915

R150 Certificate of patent or registration of utility model

Ref document number: 6946575

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250